§ 520.1326b Mebendazole and trichlorfon paste.

(a) Specifications. Each gram of paste contains 100 milligrams of mebendazole and 454 milligrams of trichlorfon.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 8.8 milligrams of mebendazole and 40 milligrams of trichlorfon per kilogram of body weight.

(2) Indications for use. It is used in horses for treatment of infections of bots (Gastrophilus intestinalis and G. nasalis), large roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, and pinworms (Oxyuris equi).

(3) Limitations. Do not administer more than once every 30 days. Do not treat sick or debilitated animals, foals under 4 months of age, or mares in the last month of pregnancy. Trichlorfon is a cholinesterase inhibitor. Do not administer simultaneously or within a few days before or after treatment with, or exposure to, cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not administer intravenous anesthetics, especially muscle relaxants, concurrently. Not for use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1330 Meclofenamic acid granules.

(a) Chemical name. N-(2,6-Dichloromethyl) anthranilic acid.

(b) Specifications. The drug is in granular form containing 5 percent meclofenamic acid.

(c) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(d) Conditions of use. (1) The drug is used in horses for the treatment of acute or chronic inflammatory diseases involving the musculoskeletal system.

(2) It is administered orally at a dosage of 1 milligram per pound of body weight (1 gram per 1,000 pounds) once daily for 5 to 7 days by addition to the daily grain ration.

(3) Treatment beyond the initial 5- to 7-day period may be indicated. A maintenance dosage level should be individualized for each animal.

(4) This drug should not be administered to horses with active gastrointestinal, hepatic, or renal disease.

(5) Not for use in horses intended for food.

(6) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[41 FR 5632, Feb. 9, 1976, as amended at 53 FR 23390, June 22, 1988]

§ 520.1331 Meclofenamic acid tablets.

(a) Specifications. Each tablet contains either 10 or 20 milligrams of meclofenamic acid.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 1.1 milligrams per kilogram (0.5 milligram per pound) daily for 5 to 7 days.

(2) Indications for use. For the relief of signs and symptoms of chronic inflammatory disease involving the musculoskeletal system.

(3) Limitations. For oral use only. Should not be administered to animals with congestive heart failure or active gastrointestinal, hepatic, or renal disease. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1341 Megestrol acetate tablets.

(a) Specifications. Each tablet contains 5 or 20 milligrams of megestrol acetate.

(b) Sponsor. No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in female dogs for the postponement of estrus and the alleviation of false pregnancy.

(2) It is administered orally, intact, or crushed and mixed with food as follows:

(i) For the postponement of estrus by proestrus treatment, 1 milligram per pound of body weight per day for 8 days.

(ii) For the postponement of estrus by anestrus treatment, 0.25 milligram per pound of body weight per day for 32 days.
(iii) For alleviation of false pregnancy, 1 milligram per pound of body weight per day for 8 days.
(3) Full dosage regimen must be completed to produce the desired effect.
(4) Examination of vaginal smears is recommended to confirm detection of proestrus.
(5) Do not administer for more than two consecutive treatments.
(6) Once therapy is started, the animal should be confined for 3 to 8 days or until cessation of bleeding, since dogs in proestrus accept a male.
(7) Do not use prior to or during first estrus cycle.
(8) Do not use in pregnant animals.
(9) Do not use in the presence of a disease of the reproductive system or with mammary tumors.
(10) Should estrus occur within 30 days after cessation of treatment, mating should be prevented.

(b) Sponsor. See No. 043264 in §510.600 of this chapter.
(c) Conditions of use in cats—(1) Amount. The starting dose is 2.5 mg every 12 hours. Following 3 weeks of treatment, the dose should be titrated to effect based on individual serum total T4 levels and clinical response.
(2) Indications for use. For the treatment of hyperthyroidism.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1350 Meloxicam.
(a) Specifications. Each milliliter of suspension contains 0.5 or 1.5 milligrams (mg) meloxicam.
(b) Sponsor. See No. 000010 in §510.600(c) of this chapter for uses as in paragraph (c) of this section.
(c) Conditions of use in dogs—(1) Amount. Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatment after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1372 Methimazole.
(a) Specifications. Each tablet contains 2.5 or 5 milligrams (mg) methimazole.
(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. The starting dose is 2.5 mg per day divided into two or three doses. The dose should be titrated to effect based on individual serum total T4 levels and clinical response.
(2) Indications for use. For the treatment of hyperthyroidism.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1408 Methylprednisolone tablets.
(a) Specifications. Each tablet contains 1, 2, or 4 milligrams of methylprednisolone.
(b) Sponsor. See No. 0000009 in §510.600(c) of this chapter for use of 1- and 2-milligram tablets; see No. 000010 for use of 1- and 2-milligram tablets.
(c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed and found effective. NADA’s for approval of drugs for these conditions of use need not include effectiveness data specified by §514.111 of this chapter, but may require bioequivalency and safety information.